Blood Loss
Conditions
Keywords
phonocardiographic measurements
Brief summary
Blood volume measurements are a critical step in the emergency care of trauma patients. The typical approach to this is to rely on historical information, physical examination and metrics such as heart rate. There is currently no good real-time measure to track blood volume. This study investigates the use of phonocardiography (listening to the sounds made by the heart) to track changes in central blood volume.
Detailed description
Blood draw subjects: Participation in this study group may last up to 60 minutes. Participants will begin with a brief medical exam to determine eligibility. This will include a review of any history of cardiovascular disease and of medications. Prior to a scheduled blood draw, eligible participates will have physiological measurements taken, which may include phonocardiographic measurements, cardiac output, plethysmography (volume changes), multifrequency bioimpedance, thoracic impedance, heart rate, blood pressure, pulse oximetry, continuous non-invasive hematocrit measurement, and respiration. The phonocardiographic measurements may be taken with both a commercial and a custom-built device. These are all non-invasive measurements. After 15 minutes of baseline measurements, a blood draw will proceed normally while the physiological measurements continue. After the participant is finished donating blood, the participant will be asked to stay in place for an additional 15 minutes to continue to collect physiological data. Participants are asked not to eat or drink during the 15 minutes as this will provide better data collection. The information collected as data for this study includes: information about medical history, body measurements, and physiological measurements.
Interventions
DIAGNOSTIC_TESTphonocardiographic measurement: InnoVital Systems
The instrument consists of one or more low-profile microphones in plastic housings with nitrile or silicon diaphragms. These sensors convert heart sounds into analog signals that will be acquired by the BIOPAC data acquisition system.
DIAGNOSTIC_TESTphonocardiographic measurement: ThinkLabs StethOne
This device senses heart sounds and may be listened to using headphones and converted to an analog signal and saved using the BIOPAC data acquisition system.
DIAGNOSTIC_TESTphysiological measurements: BIOPAC
Non-invasive blood pressure, electrocardiogram, heart rate, respiratory rate, and leg circumference - This is a commercially available device used regularly in health care settings to monitor continual blood pressure and heart rate.
DIAGNOSTIC_TESTphysiological measurements: Masimo Radical-7
A commercially available device for pulse oximetry and continuous non-invasive hematocrit measurement.
DIAGNOSTIC_TESTphysiological measurements: CoVa Monitoring System 2
This device will be used for thoracic bioimpedance and other physiological measures. This is a commercially available device. It also measures ECG, heart rate, heart rate variability, estimated stroke volume, and estimated cardiac output. The study team may measure either while body bioimpedance or thoracic bioimpedance.
DIAGNOSTIC_TESTThoracic impedance
Thoracic impedance is measured using the Starling device (https://usstarling.baxter.com/starling-system). Baxter uses a series of proprietary algorithms to infer stroke volume and cardiac output from thoracis impedance. Calculated values will be recorded, but the main variable that will be recorded is simply the temporal profile of thoracic impedance during the manipulations in each group (changing lower body negative pressure or therapeutic phlebotomy).
Sponsors
Dartmouth-Hitchcock Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
Lower Body Negative Pressure (LBNP) participants: Inclusion Criteria: * In generally good health * Free of systemic diseases * No contraindications to LBNP exposure. * No prior history of cardiovascular disease * Normal resting systolic blood pressure (SBP, 100-140 mm Hg) and diastolic blood pressure (DBP, 60-90 mm Hg).
Exclusion criteria
* Individuals who, after lying supine for five minutes, show a greater than 10 mm Hg drop in systolic pressure or a greater than 20 beats/minute increase in heart rate with standing during pre-enrollment evaluation Blood draw participants: Inclusion Criteria: * In generally good health * Free of systemic diseases * No current or prior history of cardiovascular disease or cardiovascular reactive drugs * Blood donors through the DHMC blood donation center * Healthy volunteers * People who are taking part in another study where about 500 ml of blood is being drawn * Therapeutic phlebotomy patients (hemochromatosis or polycythemia vera patients)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in cardiac cycle time intervals | Through study completion; 3 hours | Cardiac systolic and diastolic times |
| Change in phonographic characteristics - amplitude | Through study completion; 3 hours | Size of cardiac systolic and diastolic heart tones |
| Change in phonographic characteristics - frequency | Through study completion; 3 hours | Frequency content of cardiac tones |
Countries
United States
Outcome results
None listed